May 29, 2007 — The FDA has cleared the CORDIS ENTERPRISE Vascular Reconstruction Device and Delivery System under the Humanitarian Device Exemption — it is used with embolic coils for the treatment of intracranial aneurysms. It consists of a self-expanding stent and a delivery system. The stent serves as a scaffold for embolic coils to prevent herniation of the coils into the parent vessel.
The stent is a self-expanding, metal (nitinol) mesh in the shape of a tube. The delivery system is composed of an introducer and delivery wire and is used to deliver the stent to the treatment site in the neurovasculature.
Product and indication details include:
• Advance stent system through microcatheter.
• Position the stent by aligning the stent positioning marker of the delivery wire with the target site.
• Unsheath to deploy.
• Carefully retract the microcatheter, while maintaining the position of the delivery wire, to allow the stent to deploy across the neck of the aneurysm.
• The stent will expand as it exits the microcatheter.
• Maintain distal access.
• Exchange microcatheter for coiling procedure.
• Proceed with coiling procedure through stent cells.
The CORDIS ENTERPRISE is intended for use with embolic coils for the treatment of wide-neck, intracranial, saccular or fusiform aneurysms. The stent serves as a scaffold for embolic coils to prevent herniation of the coils into the parent vessel.
The device should not be used in patients who or in whom:
• the aneurysm size and/or parent vessel size does not fall within the indicated range
• cannot take blood-thinning (antiplatelet and/or anticoagulation) drugs to help prevent blood clots
• the angiography demonstrates the anatomy is not appropriate for endovascular treatment
For more information visit www.fda.gov/cdrh/pdf6/h060001b.pdf
October 16, 2024 
